PFIZER INC ($NYSE:PFE) reported no changes in both revenue and net income for the second quarter of FY2023, which ended on June 30 2023. Total revenue for the quarter was USD 12.7 billion, while net income reported was USD 2.3 billion. The results were released on August 9 2023.
On Wednesday, August 9, 2023, PFIZER INC released its second quarter earnings results for the fiscal year 2023. The company’s stock opened at $35.6 and closed at $35.8, up by 0.6% from previous closing price of 35.6. The results were reported to be encouraging and the company’s stock received a boost in the market.
The report was well-received by investors and analysts alike and shares of PFIZER INC gained strength in the market. The positive report is expected to bring further stability to the company in the upcoming months. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Pfizer Inc. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Pfizer Inc. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Pfizer Inc. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Pfizer Inc are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
Analysis – Pfizer Inc Stock Intrinsic Value
GoodWhale recently conducted an analysis of PFIZER INC‘s wellbeing. Our proprietary Valuation Line calculated the intrinsic value of PFIZER INC share to be around $45.9. Currently, the stock is traded at $35.8, representing a 22.0% undervaluation. This implies that long-term investors are in a very good position to benefit from the current price levels. More…
Risk Rating Analysis
Star Chart Analysis
In the pharmaceutical industry, competition is fierce between companies striving to bring innovative new drugs to market. Among the leaders in this industry are Pfizer Inc and its competitors Astellas Pharma Inc, Roche Holding AG, and AstraZeneca PLC. While each company has its own strengths and weaknesses, they all share a commitment to research and development in an effort to stay ahead of the competition.
– Astellas Pharma Inc ($TSE:4503)
Astellas Pharma Inc is a Japanese pharmaceutical company with a market cap of 3.61T as of 2022. The company’s ROE is 6.6%. Astellas Pharma is engaged in the research, development, manufacture, and marketing of pharmaceutical products. The company’s products include ethical drugs, over-the-counter drugs, and generic drugs. Astellas Pharma also has a clinical research division that conducts clinical trials of new drugs.
Roche Holding AG is a multinational pharmaceutical company headquartered in Basel, Switzerland. The company was founded in 1896 by Fritz Hoffmann-La Roche. Roche is the world’s largest biotech company, with products in the areas of pharmaceuticals, diagnostics, and consumer health. The company’s mission is to “improve lives by enabling people to do more, feel better, and live longer.”
Roche Holding AG has a market cap of 270.34B as of 2022, a Return on Equity of 47.83%. The company’s strong market position and financial performance are due to its innovative products and services, which address a broad range of medical needs. Roche is committed to research and development, and has a strong pipeline of new products in development. The company’s focus on customer needs and its ability to bring new products to market quickly have resulted in strong financial performance and shareholder value.
– AstraZeneca PLC ($LSE:AZN)
AstraZeneca PLC is a pharmaceutical company with a market cap of 152.81 billion as of 2022. The company has a return on equity of -0.94%. AstraZeneca PLC is engaged in the research, development, manufacture, and marketing of prescription pharmaceuticals and biologic products for the treatment of cardiovascular, gastrointestinal, infection, neuroscience, oncology, and respiratory diseases.
Pfizer Inc produced a stable performance in its second quarter of FY2023, as its total revenue remained unchanged while its net income remained flat. This result may be seen as a positive sign to investors, as the company was able to report a strong performance during a period of economic uncertainty. Investors should keep an eye on Pfizer’s long-term prospects, as the company continues to focus on expanding its product portfolio and launching new drugs to drive future growth. Additionally, Pfizer’s strong balance sheet should provide further assurance for potential investors, as the company continues to generate healthy cash flows.